LIFE aTyr Pharma Inc.

0.51
+0.01  (+1%)
Previous Close 0.5
Open 0.5
Price To Book 0.39
Market Cap 15312007
Shares 30,023,543
Volume 135,326
Short Ratio
Av. Daily Volume 255,304

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 final data presented October 5, 2017 at the International Annual Congress of the World Muscle Society (WMS).
Resolaris
Early onset facioscapulohumeral muscular dystrophy (FSHD)
Phase 1b/2 data released December 13, 2016 with further update at EASL April 2017.
Resolaris
Limb girdle muscular dystrophy (LGMD) 2B / Adult patients with facioscapulohumeral muscular dystrophy (FSHD)
Phase 1/2 patient trial to be initiated 4Q 2018.
ATYR1923
Pulmonary sarcoidosis